

New treatments outperforming placebo becoming less common

June 14 2013



The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of *Health Affairs*.

(HealthDay)—The efficacy of new medical treatments compared with placebo has sharply declined over the last few decades, suggesting that comparative effectiveness studies are needed, according to a study published in the June issue of *Health Affairs*.

Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and Steven C. Marcus, Ph.D., from the University of Pennsylvania in Philadelphia, randomly selected and analyzed 315 placebo-controlled trials published in *BMJ*, the *Journal of the American Medical Association*, *The Lancet*, and the *New England Journal of Medicine* from 1966 to 2010.



The researchers found that the average effect size or average difference in efficacy fell significantly between the active treatment and placebo, from a peak odds ratio of 4.51 (1971 to 1980) to 1.36 (2001 to 2010).

"A decline in effect sizes in conventional placebo-controlled trials supports an increased emphasis on other avenues of research, including comparative studies on the safety, tolerability, and cost of treatments with established efficacy," Olfson and colleagues conclude.

More information: Abstract

Full Text (subscription or payment may be required)

<u>Health News</u> Copyright © 2013 <u>HealthDay</u>. All rights reserved.

Citation: New treatments outperforming placebo becoming less common (2013, June 14) retrieved 20 April 2024 from

https://medicalxpress.com/news/2013-06-treatments-outperforming-placebo-common.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.